Amphastar Pharmaceuticals reported strong Q4 2021 results, with net revenues reaching $120.9 million and a GAAP net income of $19.8 million, driven by the growth of higher-margin products.
Net revenues for the fourth quarter were $120.9 million.
GAAP net income for the fourth quarter was $19.8 million, or $0.39 per share.
Adjusted non-GAAP net income for the fourth quarter was $20.8 million, or $0.42 per share.
Financial strength was driven by the continued growth of higher-margin products.
The company expects a number of pipeline milestones to be reached in 2022 as it continues to execute the Company’s strategy.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance